IGF-I, IGF-II, IGF binding protein 1, and C-peptide in second trimester amniotic fluid are dependent on gestational

Related Experiment Video

Updated: Oct 19, 2026

Generation of the Early-Gestational Maternal Immune Activation Mouse Model to Assess Prenatal Inflammation on Neurodevelopment
08:53

Generation of the Early-Gestational Maternal Immune Activation Mouse Model to Assess Prenatal Inflammation on Neurodevelopment

Published on: March 24, 2026

J Verhaeghe1, W Coopmans, E van Herck

  • 1Department of Obstetrics and Gynecology, Katholieke Universiteit Leuven, Belgium.

Pediatric Research
|July 10, 1999
PubMed

Insights

Amniotic fluid insulin-like growth factor binding protein 1 (IGFBP1) levels increase with gestational age and correlate with IGF-I and IGF-II. High IGFBP1 does not predict small for gestational age newborns but is linked to lower placental weight.

Area of Science:

  • Reproductive biology
  • Endocrinology
  • Maternal-fetal medicine

Background:

  • Previous studies suggested a link between small for gestational age newborns and increased amniotic fluid insulin-like growth factor binding protein 1 (IGFBP1).
  • Understanding the role of IGFBP1 and related growth factors in early pregnancy is crucial for fetal development assessment.

Purpose of the Study:

  • To investigate the relationship between amniotic fluid (AF) concentrations of IGFBP1, IGF-I, IGF-II, and C-peptide and gestational age.
  • To determine if AF IGFBP1 levels correlate with fetal growth, specifically birth weight and placental weight.

Main Methods:

  • Developed a radioimmunoassay (RIA) for IGFBP1.
  • Measured IGFBP1, IGF-I, IGF-II, and C-peptide in 209 amniotic fluid samples from 14-20 weeks gestation.
  • Correlated AF factor concentrations with gestational age, birth weight, and placental weight.

Main Results:

  • AF IGFBP1, IGF-I, and IGF-II concentrations increased with gestational age and were higher than in third-trimester cord serum.
  • AF IGFBP1 levels correlated strongly with AF IGF-I and IGF-II after adjusting for gestational age.
  • No correlation was found between AF growth factors and birth weight after adjusting for gestational age.
  • Placental weight and placental weight to birth weight percentage were negatively correlated with AF IGF-I, IGF-II, and IGFBP1.

Conclusions:

  • AF IGFBP1 concentrations rise gradually between 14-20 weeks gestation and are associated with IGF-I and IGF-II levels.
  • Elevated AF IGFBP1 levels do not predict small for gestational age newborns.
  • Higher AF IGFBP1 levels are associated with reduced placental weight, suggesting a role in placental development or function.

More Related Videos

Mouse In Vivo Placental Targeted CRISPR Manipulation07:39

Mouse In Vivo Placental Targeted CRISPR Manipulation

Published on: April 14, 2023

Related Concept Videos

Transcytosis of IgG01:15

Transcytosis of IgG

Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...